Morgan RD, Banerjee S, Hall M, et al. - Researchers report a phase 1b and randomised phase 2 trial performed on patients with recurrent, epithelial ovarian cancer with a platinum-free interval (PFI) of 3 to 12 months, to define the safety as well as the efficacy of pazopanib with fosbretabulin. Based on PFI (> 6 vs ≤ 6 months) and previous bevacizumab use, the participants were stratified. Hypertension (100%), neutropenia (50%), fatigue (50%), vomiting (50%) were reported as the commonest grade ≥ 2 adverse events. Fosbretabulin 54 mg/m² on days 1, 8 and 15 and pazopanib 600 mg once daily (od), every 28 days, was suggested as the phase 2 dose level, which was compared with pazopanib 800 mg od in a randomised phase 2 trial. Findings did not afford enough clarity to demonstrate that pazopanib with fosbretabulin affords an efficacious regimen to treat epithelial ovarian cancer. To improve tolerability and maximize patient safety in future trials, it is required to ensure effective cardiac risk mitigation.